2025-11-11T13:48:00-06:00 2024-12-31 991856619 GRANT THORNTON ADVISORS LLC 53 STATE STREET SUITE 1600 BOSTON MA 02109 990 2024-01-01 390807235 VERSITI WISCONSIN INC VERS 4149335000 PO BOX 2178 MILWAUKEE WI 532012178 CHRIS MISKEL PRESIDENT & CEO 4149335000 2025-11-11 1 0 ERIN COUTURE P01390592 6177237900 2024 2025-03-06 01:10:19Z CHRIS MISKEL PO BOX 2178 MILWAUKEE WI 532012178 303566482 0 X WWW.VERSITI.ORG X 1947 WI (SEE SCHEDULE O) 18 17 1342 289 4207653 6612 35533265 47346648 195099800 228515997 3894142 4323810 677285 833792 235204492 281020247 3971528 4046177 0 0 99706668 112637915 0 0 0 127290428 146956995 230968624 263641087 4235868 17379160 188812448 213041862 68196230 75346695 120616218 137695167 X VERSITI WISCONSIN, INC. (VERSITI) IS A BLOOD HEALTH INNOVATOR WHICH ENHANCES LIVES THROUGH DISCOVERY, DIAGNOSIS AND TREATMENT. VERSITI EXPANDS THE FRONTIERS OF PATIENT HEALTH THROUGH THE INTEGRATION OF SCIENCE, MEDICINE AND SERVICE. 0 0 58410965 129750 66310411 VERSITI OPERATES THE COMPREHENSIVE CENTER FOR BLEEDING DISORDERS (CCBD) UNDER A FEDERAL SUBAWARD AGREEMENT OF THE SOCIAL SECURITY ACT, PROVIDING SPECIALIZED DIAGNOSIS, TREATMENT, AND SUPPORTIVE CARE TO PATIENTS WITH INHERITED AND ACQUIRED BLEEDING AND CLOTTING DISORDERS. AS PART OF VERSITI'S MISSION TO IMPROVE PATIENT OUTCOMES, CCBD DELIVERS COMPREHENSIVE CARE THROUGH A MULTIDISCIPLINARY TEAM OF HEMATOLOGISTS, NURSES, SOCIAL WORKERS, AND SPECIALIZED STAFF. IN 2024, CCBD PROVIDED CRITICAL SERVICES TO PATIENTS WITH BLEEDING DISORDERS AND THEIR FAMILIES, INCLUDING FOR HEMOPHILIA A AND B, VON WILLEBRAND DISEASE, AND OTHER RARE COAGULATION DISORDERS. CCBD PROVIDED 17,470 SPECIALTY PHARMACY PRODUCTS IN 2024 AND CONTINUES TO BE A FEDERALLY RECOGNIZED HEMOPHILIA TREATMENT CENTER (HTC). AS A (CONTINUED IN SCHEDULE O) COVERED ENTITY UNDER THE 340B DRUG DISCOUNT PROGRAM, VERSITI ACCESSES SPECIALTY PHARMACEUTICALS AT DISCOUNTED PRICING, PASSING SAVINGS ON TO PATIENTS AND REDUCING COSTS TO THE HEALTHCARE SYSTEM WHILE ENSURING PHARMACEUTICAL NET INCOME SUPPORTS PROGRAM ACTIVITIES INCLUDING PATIENT CARE, EDUCATION, SUPPORT SERVICES, AND APPROVED RESEARCH. VERSITI PROVIDES THESE SPECIALTY PHARMACY PRODUCTS TO HOME CARE PATIENTS AND HOSPITAL SYSTEMS, IMPROVING MEDICATION ACCESS AND ADHERENCE. THE CENTER'S COMPREHENSIVE SERVICES INCLUDE FACTOR REPLACEMENT THERAPY, PROPHYLACTIC TREATMENT PROTOCOLS, GENETIC COUNSELING, AND PATIENT EDUCATION PROGRAMS DESIGNED TO HELP INDIVIDUALS WITH BLEEDING DISORDERS LIVE FULL, ACTIVE LIVES. THROUGH SPECIALIZED EXPERTISE, FEDERAL PARTNERSHIP, AND COMPASSIONATE CARE, CCBD SERVES AS A PREMIER RESOURCE FOR BLEEDING DISORDER TREATMENT, IMPROVING OUTCOMES WHILE REDUCING HEALTHCARE COSTS FOR PATIENTS WITH THESE COMPLEX CONDITIONS. 47161515 77971 54769275 VERSITI WISCONSIN RECRUITS VOLUNTEER BLOOD DONORS AND COLLECTS, PROCESSES, AND DISTRIBUTES BLOOD PRODUCTS AS PART OF ITS MISSION TO PROVIDE A SAFE AND RELIABLE BLOOD SUPPLY FOR HOSPITALS AND HEALTHCARE SYSTEMS ACROSS WISCONSIN. VERSITI'S COMPREHENSIVE BLOOD INVENTORY INCLUDES RED BLOOD CELLS, PLATELETS, PLASMA, AND SPECIALIZED PRODUCTS DESIGNED TO MEET PATIENT NEEDS. IN 2024, VERSITI WISCONSIN COLLECTED TOTAL RED BLOOD CELLS AND PLATELETS OF 152,765, SERVING 62 HOSPITALS. THE ORGANIZATION HOSTED 2,808 COMMUNITY BLOOD DRIVES, ENGAGING 56,626 VOLUNTEER DONORS WHO CONTRIBUTED TO VERSITI'S LIFESAVING MISSION. (CONTINUED IN SCHEDULE O)INNOVATION AND EMERGENCY RESPONSE: DURING 2024, VERSITI WISCONSIN PARTNERED WITH MILWAUKEE COUNTY TO LAUNCH AN INNOVATIVE EMS PREHOSPITAL WHOLE BLOOD TRANSFUSION PROGRAM FOR CRITICALLY INJURED TRAUMA PATIENTS, THE FIRST SUCH PARTNERSHIP IN WISCONSIN. COMMUNITY PARTNERSHIPS: AS A VITAL PARTNER IN PUBLIC HEALTH, VERSITI WISCONSIN PARTICIPATED IN THE #KNOWSCD SICKLE CELL DISEASE AWARENESS CAMPAIGN, THE WE GIVE BLOOD DRIVE PARTNERSHIP WITH ABBOTT AND THE BIG TEN CONFERENCE DURING THE 2024 FOOTBALL SEASON, AND THE ORGANIZATION'S VERSITI ON KING COMMUNITY CENTER CONDUCTED BLOOD TYPING EVENTS FOR 140 INDIVIDUALS, IDENTIFYING 43 POTENTIAL RO DONORS TO SUPPORT PATIENTS WITH SICKLE CELL DISEASE. INFRASTRUCTURE AND OPERATIONS: VERSITI WISCONSIN OPERATES DONOR CENTERS AND MOBILE COLLECTION UNITS THROUGHOUT THE STATE. IN 2024, THE ORGANIZATION COMPLETED 4 DONOR CENTER RENOVATIONS TO IMPROVE DONOR COMFORT, ENHANCE OPERATIONAL EFFICIENCY, AND EXPAND COLLECTION CAPACITY. THROUGH DEDICATED VOLUNTEER DONORS AND STRATEGIC COMMUNITY PARTNERSHIPS, VERSITI WISCONSIN MAINTAINS A ROBUST BLOOD SUPPLY THAT ENABLES HOSPITALS TO PROVIDE CRITICAL CARE, EMERGENCY SERVICES, AND LIFESAVING TREATMENTS TO PATIENTS THROUGHOUT THE REGION. 39725349 3812500 0 VERSITI RESEARCH ADVANCES SCIENTIFIC DISCOVERY AND PATIENT CARE THROUGH COMPREHENSIVE SUPPORT OF BLOOD-RELATED RESEARCH, EDUCATION, AND COMMUNITY ENGAGEMENT PROGRAMS. ROOTED IN ITS NONPROFIT MISSION, VERSITI ENABLES GROUNDBREAKING BLOOD RESEARCH WHILE FOSTERING THE NEXT GENERATION OF SCIENTISTS AND IMPROVING THE LIVES OF PATIENTS AFFLICTED BY BLOOD DISORDERS. IN 2024, VERSITI RESEARCHERS PUBLISHED 122 PEER-REVIEWED MANUSCRIPTS WITH 45 FEATURING VBRI FACULTY AS LEAD OR SENIOR AUTHORS, INCLUDING 5 PUBLICATIONS IN JOURNALS WITH IMPACT FACTORS EXCEEDING 30. 7 IN JOURNALS WITH IMPACT FACTORS BETWEEN 20 AND 30, AND 17 IN JOURNALS WITH IMPACT FACTORS BETWEEN 10 AND 20. VERSITI'S RESEARCH SPANS 5 MAJOR PROGRAMS: TRANSFUSION MEDICINE, VASCULAR BIOLOGY, AND CELLULAR THERAPY; THROMBOSIS AND (CONTINUED IN SCHEDULE O) HEMOSTASIS; STEM CELL BIOLOGY AND HEMATOPOIESIS; IMMUNOLOGY; AND TRANSLATIONAL HEMATOLOGY. VERSITI'S RESEARCH GRANT TEAMS PROCESSED APPROXIMATELY $41M IN NEW MULTI-YEAR GRANTS AND SUBMITTED 112 PROPOSALS TOTALING $140.13M IN 2024. VERSITI ALSO LEADS THROUGH COLLABORATIVE BLOOD SCIENCE INITIATIVES SUCH AS IN VENUS (VENOUS THROMBOEMBOLISM NETWORK US) AND REDS-IV-P (RECIPIENT EPIDEMIOLOGY AND DONOR EVALUATION STUDY), NATIONAL PROGRAMS ADVANCING THROMBOSIS TREATMENT AND BLOOD TRANSFUSION SAFETY. OPERATING IN AN 82,000 SQUARE-FOOT FACILITY, VERSITI IS HOME TO 213 RESEARCH STAFF, INCLUDING 35 INVESTIGATORS AND 22 RESEARCH SCIENTISTS, IN 2024. EDUCATIONAL INITIATIVES INCLUDE GRADUATE TRAINING, RESEARCH SYMPOSIA, AND COLLABORATIVE PARTNERSHIPS IN THE MILWAUKEE REGIONAL MEDICAL CENTER, SUCH AS THE MRMC HEMATOLOGY BIOREPOSITORY, WHICH PROVIDES ANNOTATED BIOLOGICAL SAMPLES FOR BIOMARKER DISCOVERY FOR CLINICAL PARTNERS THROUGHOUT CAMPUS. 83154607 25956 107438365 MSI:THE VERSITI MEDICAL SERVICES INSTITUTE (MSI) ADVANCES PATIENT CARE THROUGH SPECIALIZED TREATMENT AND TRANSLATIONAL RESEARCH THAT BRIDGES CLINICAL MEDICINE AND LABORATORY SCIENCE, FOSTERING COLLABORATION BETWEEN PHYSICIAN-SCIENTISTS AND BASIC RESEARCHERS TO ACCELERATE MEDICAL DISCOVERIES. ESTABLISHED IN 2009 AND SUPPORTED BY VERSITI AND THE VERSITI BLOOD RESEARCH INSTITUTE FOUNDATION, MSI ENABLES PHYSICIANS TO DEDICATE PROTECTED TIME TO CLINICAL RESEARCH WHILE MAINTAINING PATIENT CARE RESPONSIBILITIES. IN 2024, VERSITI PHYSICIAN-SCIENTISTS PERFORMED 3,686 THERAPEUTIC PROCEDURES. AS PART OF VERSITI'S MISSION TO ADVANCE EVIDENCE-BASED MEDICINE, MSI OPERATES THE CLINICAL TRIALS & RESEARCH OFFICE (CTRO) TO CONDUCT FDA-REGULATED CLINICAL STUDIES IN SPECIALIZED AREAS INCLUDING ALLOIMMUNE PLATELET DISORDERS, TRANSFUSION-INDUCED ACUTE LUNG INJURY, AND DRUG-INDUCED BLOOD DISORDERS. THROUGH MENTORSHIP, PROTECTED RESEARCH TIME, AND COLLABORATIVE INFRASTRUCTURE, MSI PROVIDES DEEP CLINICAL EXPERTISE AND TRANSFORMS CLINICAL QUESTIONS INTO SCIENTIFIC DISCOVERIES THAT BENEFIT PATIENTS WITH BLOOD DISORDERS NATIONWIDE.DONOR TESTING:THE VERSITI DONOR TESTING LABORATORY (DTL) PROVIDES INFECTIOUS DISEASE TESTING TO DETERMINE DONOR SUITABILITY AND PRODUCT SAFETY FOR ORGANS, TISSUES, HEMATOPOIETIC STEM CELLS, AND CORD BLOOD. THE DTL OFFERS NUCLEIC ACID TESTING, ANTIBODY SCREENING, AND CONFIRMATORY TESTING FOR MANY DIFFERENT DISEASE STATES. AS PART OF VERSITI'S MISSION TO MAINTAIN THE SAFEST POSSIBLE BLOOD SUPPLY, DONOR TESTING OPERATIONS CONDUCT MANDATORY SCREENING FOR TRANSFUSION-TRANSMISSIBLE INFECTIONS AS REQUIRED BY FDA REGULATIONS. THE DTL UTILIZES STATE-OF-THE-ART NUCLEIC ACID TESTING (NAT) TECHNOLOGY AND SEROLOGICAL METHODS TO DETECT INFECTIOUS AGENTS. VERSITI'S DTL SUPPORTS BLOOD COLLECTION ACTIVITIES ACROSS VERSITI'S ENTIRE GEOGRAPHIC FOOTPRINT WHILE MAINTAINING RIGOROUS QUALITY STANDARDS AND REGULATORY COMPLIANCE. VERSITI'S DONOR TESTING SERVICES STRENGTHEN THE NATIONAL BLOOD SUPPLY INFRASTRUCTURE. BY ENSURING COMPREHENSIVE DONOR SCREENING, VERSITI PROTECTS PATIENTS WHO DEPEND ON SAFE BLOOD TRANSFUSIONS, STRENGTHENS THE NATIONAL BLOOD SUPPLY, AND SUPPORTS THE BROADER PUBLIC HEALTH MISSION OF MAINTAINING CONFIDENCE IN A HIGH-QUALITY BLOOD SUPPLY.DIAGNOSTIC LABS:VERSITI SERVES PATIENTS, PHYSICIANS, AND HOSPITALS BY PROVIDING COMPREHENSIVE CLINICAL DIAGNOSTIC TESTING SERVICES THAT SUPPORT ACCURATE DIAGNOSIS, TREATMENT MONITORING, AND PATIENT CARE ACROSS MULTIPLE MEDICAL SPECIALTIES. AS PART OF VERSITI'S MISSION TO ADVANCE HEALTHCARE THROUGH LABORATORY EXCELLENCE, THE DIAGNOSTIC LABORATORIES DELIVER SPECIALIZED TESTING SERVICES INCLUDING HEMATOLOGY, COAGULATION, IMMUNOHEMATOLOGY, INFECTIOUS DISEASE, MOLECULAR DIAGNOSTICS, FLOW CYTOMETRY, AND REFERENCE LABORATORY SERVICES. DURING 2024, VERSITI CONDUCTED 148,545 DIAGNOSTIC TESTING SERVICES FOR HOSPITALS, PHYSICIAN OFFICES, AND REFERENCE LABORATORIES. VERSITI'S DIAGNOSTIC LABORATORIES MAINTAIN STATE-OF-THE-ART INSTRUMENTATION AND RIGOROUS QUALITY ASSURANCE PROGRAMS TO ENSURE ACCURATE, TIMELY RESULTS THAT GUIDE CLINICAL DECISION-MAKING AND IMPROVE PATIENT OUTCOMES. THE LABORATORIES PROVIDE SPECIALIZED EXPERTISE IN BLOOD-RELATED DISORDERS, OFFERING ADVANCED TESTING CAPABILITIES INCLUDING PLATELET FUNCTION ANALYSIS, COAGULATION STUDIES, RED BLOOD CELL ANTIGEN TYPING, AND COMPLEX IMMUNOHEMATOLOGY WORKUPS THAT CONFIRM AND ENSURE TRANSFUSION SAFETY. VERSITI'S DIAGNOSTIC LABORATORIES SERVE AS A VITAL HEALTHCARE INFRASTRUCTURE RESOURCE, PROVIDING 24/7 TESTING SUPPORT FOR EMERGENCY DEPARTMENTS AND CRITICAL CARE UNITS. THROUGH COMPREHENSIVE DIAGNOSTIC TESTING SERVICES, ADVANCED LABORATORY EXPERTISE, AND COMMITMENT TO QUALITY, VERSITI'S DIAGNOSTIC LABORATORIES STRENGTHEN THE HEALTHCARE SYSTEM BY ENABLING ACCURATE DIAGNOSIS AND OPTIMAL PATIENT CARE ACROSS THE STATE.ORGAN AND TISSUE:VERSITI ORGAN AND TISSUE OPERATES AS SOUTHEASTERN WISCONSIN'S FEDERALLY DESIGNATED ORGAN PROCUREMENT ORGANIZATION, COORDINATING ORGAN AND TISSUE DONATION TO SAVE AND HEAL LIVES THROUGHOUT THE STATE. ROOTED IN VERSITI'S MISSION TO ADVANCE PUBLIC HEALTH, THE ORGANIZATION FACILITATES THE GENEROUS GIFT OF DONATION BY WORKING WITH DONOR FAMILIES, HOSPITALS, AND TRANSPLANT CENTERS TO ENSURE ORGANS AND TISSUES REACH PATIENTS IN NEED. IN 2024, VERSITI ORGAN AND TISSUE COORDINATED 394 ORGAN TRANSPLANTS FROM 606 MUSCULOSKELETAL DONORS. THE ORGANIZATION PROVIDES 24/7 COORDINATION SERVICES, FAMILY SUPPORT, AND CLINICAL EXPERTISE THROUGHOUT THE DONATION PROCESS. VERSITI'S DONATION COORDINATORS AND CLINICAL STAFF WORK ALONGSIDE HOSPITAL TEAMS TO IDENTIFY POTENTIAL DONORS, SUPPORT GRIEVING FAMILIES, AND ENSURE OPTIMAL ORGAN AND TISSUE RECOVERY. THROUGH COMMUNITY EDUCATION PROGRAMS LIKE DONATE LIFE MONTH IN APRIL, VERSITI PROMOTES DONATION AWARENESS AND SUPPORTS WISCONSIN FAMILIES WHO CHOOSE THE HEALING PATH OF DONATION. BY FACILITATING ORGAN AND TISSUE DONATION, VERSITI ORGAN AND TISSUE TRANSFORMS TRAGEDY INTO HOPE, ENABLING ONE DONOR TO SAVE UP TO EIGHT LIVES THROUGH ORGAN DONATION AND HEAL DOZENS MORE THROUGH TISSUE DONATION.VCTS:VERSITI CLINICAL TRIALS SERVICES (VCTS) PROVIDES COMPREHENSIVE CLINICAL RESEARCH SERVICES TO PHARMACEUTICAL SPONSORS, BIOTECHNOLOGY COMPANIES, AND ACADEMIC INSTITUTIONS CONDUCTING CLINICAL STUDIES IN HEMATOLOGY, TRANSFUSION MEDICINE, ONCOLOGY, IMMUNOLOGY, CELL AND GENE THERAPY, AND ORPHAN AND RARE DISEASES. AS PART OF VERSITI'S MISSION TO ADVANCE MEDICAL SCIENCE, VCTS OFFERS SPECIALIZED LABORATORY SERVICES, INSTITUTIONAL REVIEW BOARD (IRB) OVERSIGHT, BIOSPECIMEN COLLECTION AND MANAGEMENT, PROJECT MANAGEMENT, AND REGULATORY SUPPORT TO ENSURE SAFE AND COMPLIANT STUDIES. VCTS LEVERAGES VERSITI'S UNIQUE EXPERTISE IN BLOOD SCIENCE AND LABORATORY DIAGNOSTICS TO SUPPORT COMPLEX TRIALS REQUIRING SPECIALIZED TESTING CAPABILITIES. THE PROGRAM MAINTAINS RIGOROUS QUALITY STANDARDS AND REGULATORY COMPLIANCE WHILE PROVIDING INNOVATIVE SOLUTIONS FOR COMPLEX CLINICAL RESEARCH CHALLENGES. THROUGH EXPERT CLINICAL RESEARCH SERVICES, VERSITI CLINICAL TRIALS ACCELERATE THE DEVELOPMENT OF NEW TREATMENTS FOR BLOOD DISORDERS AND SUPPORT THE ADVANCEMENT OF EVIDENCE-BASED MEDICINE IN HEMATOLOGY AND TRANSFUSION MEDICINE. 83154607 25956 107438365 228452436 1 1 0 1 0 0 0 0 0 1 1 1 0 0 1 1 0 1 0 0 0 0 0 0 1 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 0 1 0 0 1342 1 1 1 0 0 0 0 0 0 0 0 0 1 0 X 18 17 0 0 0 0 1 1 1 1 1 0 0 1 1 1 1 1 1 1 1 0 WI X X DAWN HENSE 4149335000 638 N 18TH ST MILWAUKEE WI 532332121 X CHRIS MISKEL PRESIDENT & CEO 23.00 32.00 X X 713940 908656 57669 FRED GEILFUSS CHAIR 1.00 5.00 X X 0 0 0 L ALAN WHALEY VICE CHAIR 1.00 4.00 X X 0 0 0 COREEN DICUS-JOHNSON JD SECRETARY 1.00 4.00 X X 0 0 0 RON MILLER TREASURER 1.00 4.00 X X 0 0 0 NICHOLAS BAUER BOARD MEMBER 1.00 4.00 X 0 0 0 DAVID GINSBURG MD BOARD MEMBER 1.00 4.00 X 0 0 0 CECELIA GORE BOARD MEMBER 1.00 4.00 X 0 0 0 GAIL HANSON BOARD MEMBER 1.00 4.00 X 0 0 0 THOMAS HAUSKE JR BOARD MEMBER 1.00 4.00 X 0 0 0 SHERRY HUSA BOARD MEMBER 1.00 4.00 X 0 0 0 DALE KENT BOARD MEMBER 1.00 4.00 X 0 0 0 ROBERT H MANEGOLD BOARD MEMBER 1.00 5.00 X 0 0 0 JEFFREY S MCDONALD BOARD MEMBER 1.00 4.00 X 0 0 0 MAGGEY OPLINGER BOARD MEMBER 1.00 4.00 X 0 0 0 JOHN PERRAS BOARD MEMBER 1.00 4.00 X 0 0 0 KATHY THORNTON-BIAS BOARD MEMBER - THRU 6/24 1.00 4.00 X 0 0 0 GREG WESLEY BOARD MEMBER 1.00 4.00 X 0 0 0 PETER ZIEGLER BOARD MEMBER 1.00 4.00 X 0 0 0 MATTHEW ANDERSON MD EVP & CHIEF MED. OFF. - AS OF 7/24 50.00 5.00 X 471868 0 65850 BRIAN BAUTISTA EVP & CHIEF OPERATING OFFICER 24.00 31.00 X 357615 455150 53592 LYNNE BRIGGS VP & CHIEF INFORMATION OFFICER 24.00 31.00 X 212020 269846 52622 BARBARA BRYANT EVP & CHIEF MED. OFF. - THRU 8/24 50.00 5.00 X 447822 0 25848 MICHAEL DEININGER MD EVP & CHIEF SCIENTIFIC OFFICER 48.00 7.00 X 637080 33530 39231 JESSICA DROUILLARD VP & CHIEF QUALITY OFFICER 24.00 31.00 X 121455 154582 18905 GITESH DUBAL EVP & CHIEF MKTG. OFF. - THRU 4/24 24.00 31.00 X 179108 227952 23781 GRETCHEN JAMESON EVP & CHIEF MKTG. OFF. - AS OF 4/24 24.00 31.00 X 96983 123432 15013 BRADLEY PIETZ EVP & CHIEF LABORATORY OFFICER 24.00 31.00 X 264400 336515 65430 BART REUTER EVP & GENERAL COUNSEL 23.00 32.00 X 379102 482498 66046 DEREK TYUS EVP & CHIEF FINANCIAL OFF. - AS 3/24 23.00 32.00 X 199013 253291 48353 ANTHONY WATKINS EVP&CFO-THRU 3/24;BUS DEV-AS OF 3/24 23.00 32.00 X 329433 419278 29876 JAMES WEIDNER EVP & CHIEF HR OFFICER 24.00 31.00 X 251504 320098 56792 KATHLEEN PUCA SR MEDICAL DIRECTOR 55.00 0.00 X 442557 0 55500 KARIN HOFFMEISTER DEPUTY DIRECTOR VBRI 55.00 0.00 X 411046 0 49328 CHRISTIAN J KASTRUP PHD SR INVESTIGATOR 55.00 0.00 X 399219 0 61882 LYNN M MALEC MD SENIOR MEDICAL DIRECTOR 55.00 0.00 X 384247 0 34890 LISA BAUMANN KREUZIGER SENIOR MEDICAL DIRECTOR 55.00 0.00 X 394936 0 40578 6693348 3984828 861186 211 0 1 0 MORTENSON CONSTRUCTION 115 S 84TH STREET STE 400 MILWAUKEE WI 53214 CONTRACTOR 6364631 HGA PO BOX 86 MINNEAPOLIS MN 55486 BUILDING DESIGN FIRM 3359610 MEDICAL COLLEGE OF WISCONSIN INC 8701 WATERTOWN PLANK RD MILWAUKEE WI 53226 RESEARCH SERVICES 2878711 HEALTH RESEARCH INC PO BOX 2966 BUFFALO NY 14240 RESEARCH SERVICES 790499 CERNER CORPORATION 2800 ROCKCREEK PARKWAY KANSAS CITY MO 64117 SOFTWARE SUPPORT 785249 35 1170 65534 10774042 32588850 3917052 47346648 PHARMACY 621500 66310411 66310411 BLOOD SERVICES 621991 54769275 54769275 DIAGNOSTIC LABS 621500 51114322 51114322 ORGAN & TISSUE 621991 26103956 26103956 BIOMATERIALS & TRIALS 621500 17724701 13745824 3978877 12493332 12493332 228515997 3849579 3849579 4483 12144 -7661 -7661 -7661 22907473 63159 22470012 26389 437461 36770 474231 474231 26200 65534 37690 -11490 -11490 AFFILIATE SERVICE FEES 900099 551381 551381 SHARED SERVICE FEE 900099 228776 228776 ACQUIRED CASH RECEIPTS 900099 66667 66667 6119 2054 4065 852943 281020247 224539174 4207653 4926772 X 4042177 4042177 4000 4000 4364390 2360124 2004266 102960 102960 84138998 72439819 11699179 4236051 3596963 639088 13961252 11754277 2206975 5834264 4905023 929241 181659 61385 120274 83827 83827 66375 66375 5895 5895 27035483 26117290 918193 876369 475391 400978 493537 473267 20270 2661427 2346892 314535 15727 15727 6611048 4378606 2232442 3119840 2594302 525538 547720 473533 74187 87941 58178 29763 6659756 5063766 1595990 99513 99513 COST OF IMPORTED PROD 54780339 54780339 MEDICAL LAB SUPPLIES 24878103 24878103 VERSITI SERVICES ALLOC 14610805 4344313 10266492 EQUIPMENT LEASE/MAINT 3621223 3076794 544429 520408 28827 491581 263641087 228452436 35188651 0 4778539 4421429 0 0 2528124 12547670 38464994 42233253 0 0 0 0 0 0 11173130 12095944 1181467 980278 140723165 89691845 40808629 51031320 44952503 46603137 17143314 16217402 0 0 25991764 24989420 1789984 1922009 188812448 213041862 49314606 56506442 0 0 3602994 2125503 0 0 0 0 0 0 0 0 0 0 15278630 16714750 68196230 75346695 X 120616218 125994810 0 11700357 120616218 137695167 188812448 213041862 X 17379160 999785 -1299996 X 0 1 X 1 1 1 X 26647932 26132948 31822899 35533265 47346648 167483692 26647932 26132948 31822899 35533265 47346648 167483692 40835796 126647896 1862957 1963086 1514098 3484842 3854062 12679045 4416 3620 3684 4273 6612 22605 100852 121241 91510 524619 622113 1460335 181645677 927868690 0.69720 0.67670 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: PATRONAGE DIVIDENDS - 2020 AMOUNT: $ 31,405. 2021 AMOUNT: $ 0. 2022 AMOUNT: $ 0. 2023 AMOUNT: $ 0. 2024 AMOUNT: $ 0. COPY FEES - 2020 AMOUNT: $ 0. 2021 AMOUNT: $ 0. 2022 AMOUNT: $ 510. 2023 AMOUNT: $ 0. 2024 AMOUNT: $ 667. MISCELLANEOUS - 2020 AMOUNT: $ 197. 2021 AMOUNT: $ 12,241. 2022 AMOUNT: $ 0. 2023 AMOUNT: $ 355. 2024 AMOUNT: $ 3,347. ACQUIRED CASH RECEIPTS - 2020 AMOUNT: $ 69,250. 2021 AMOUNT: $ 109,000. 2022 AMOUNT: $ 91,000. 2023 AMOUNT: $ 110,000. 2024 AMOUNT: $ 66,667. CREDIT CARD REBATES - 2020 AMOUNT: $ 0. 2021 AMOUNT: $ 0. 2022 AMOUNT: $ 0. 2023 AMOUNT: $ 880. 2024 AMOUNT: $ 51. AFFILIATE SERVICE FEES - 2020 AMOUNT: $ 0. 2021 AMOUNT: $ 0. 2022 AMOUNT: $ 0. 2023 AMOUNT: $ 413,384. 2024 AMOUNT: $ 551,381. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 1 0 0 0 0 0 0 1 66375 66375 0 PART II-B, LINE 1: PAID STAFF OR MANAGMENT GENERAL COUNSEL PROVIDES LOBBYING SERVICES TO THE FILING ORGANIZATION. HOWEVER, SUCH EXPENSES ARE PAID FOR BY VERSITI INC., THE FILING ORGANIZATION'S PARENT. OTHER ACTIVITIES $8,775 OF THE DUES PAID TO THE ASSOCIATION OF ORGAN PROCUREMENT ORGANIZATIONS AND $57,600 OF OTHER EXPENSES PAID WERE ALLOCATED TO LOBBYING ACTIVITIES. 104985040 784199 12490658 4744538 113515359 94766972 671355 14059961 4513248 104985040 112901289 848275 -13361785 5620807 94766972 99612019 1371435 16077669 4159834 112901289 89992682 4494881 9457908 4333452 99612019 0.98030 0.01970 0 1 1 4268493 4268493 69535581 51296417 18239164 2652452 1008230 1644222 49301473 36453151 12848322 14965166 934047 14031119 51031320 INVESTMENT IN CENETRON 16217402 F 16217402 LONG TERM RETIREMENT LIABILITIES 10895969 LEASE LIABILITY 3598811 ADDITIONAL INCENTIVES 2219970 16714750 X 281101289 999785 999785 280101504 5895 912848 918743 281020247 264022340 387148 387148 263635192 5895 5895 263641087 PART V, LINE 4: ENDOWMENTS THE FILING ORGANIZATION IS A BENEFICIARY OF THE VERSITI BLOOD RESEARCH INSTITUTE FOUNDATION'S ("VBRIF") ENDOWMENT AS A SUPPORTED ORGANIZATION. THE BOARD DESIGNATED ENDOWMENT FUNDS ARE DESIGNATED BY THE BOARD AS ENDOWMENT FUNDS TO ENSURE THE CONTINUING AVAILABILITY OF FUNDS FOR RESEARCH PURPOSES. PART X, LINE 2: INCOME TAXES VERSITI, WISCONSIN, ILLINOIS, MICHIGAN, INDIANA AND THE FOUNDATION HAVE ALL RECEIVED TAX DETERMINATION LETTERS CONFIRMING THAT THE ORGANIZATIONS QUALIFY AS TAX-EXEMPT ORGANIZATIONS UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE (IRC). THE ORGANIZATION FOLLOWS GUIDANCE THAT CLARIFIES THE ACCOUNTING FOR UNCERTAINTY IN TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN, INCLUDING ISSUES RELATING TO FINANCIAL STATEMENT RECOGNITION AND MEASUREMENT. THIS GUIDANCE PROVIDES THAT THE TAX EFFECTS FROM AN UNCERTAIN TAX POSITION CAN ONLY BE RECOGNIZED IN THE FINANCIAL STATEMENTS IF THE POSITION IS MORE LIKELY THAN NOT TO BE SUSTAINED IF THE POSITION WERE TO BE CHALLENGED BY A TAXING AUTHORITY. THE ASSESSMENT OF THE TAX POSITION IS BASED SOLELY ON THE TECHNICAL MERITS OF THE POSITION, WITHOUT REGARD TO THE LIKELIHOOD THAT THE TAX POSITION MAY BE CHALLENGED. VERSITI, WISCONSIN, ILLINOIS, MICHIGAN, INDIANA AND THE FOUNDATION ARE EXEMPT FROM FEDERAL INCOME TAX UNDER IRC SECTION 501(C)(3), THOUGH THEY ARE SUBJECT TO TAX ON INCOME UNRELATED TO THEIR EXEMPT PURPOSES, UNLESS THAT INCOME IS OTHERWISE EXCLUDED BY THE IRC. THE ORGANIZATION HAS PROCESSES PRESENTLY IN PLACE TO ENSURE THE MAINTENANCE OF ITS TAX-EXEMPT STATUS; TO IDENTIFY AND REPORT UNRELATED INCOME; TO DETERMINE ITS FILING AND TAX OBLIGATIONS IN JURISDICTIONS FOR WHICH IT HAS NEXUS; AND TO IDENTIFY AND EVALUATE OTHER MATTERS THAT MAY BE CONSIDERED TAX POSITIONS. THE ORGANIZATION FILES FEDERAL AND STATE INCOME TAX RETURNS TO REPORT UNRELATED BUSINESS INCOME WHERE APPLICABLE, AND WITH FEW EXCEPTIONS, THOSE PERIODS GENERALLY REMAIN OPEN THREE YEARS FOR FEDERAL PURPOSES AND FOUR YEARS FOR STATE PURPOSES. THE STATUTE OF LIMITATIONS WILL REMAIN OPEN FOR ANY YEARS WHERE RETURNS WERE NOT FILED. THE ORGANIZATION HAS DETERMINED THAT THERE ARE NO MATERIAL UNCERTAIN TAX POSITIONS THAT REQUIRE RECOGNITION OR DISCLOSURE IN THE CONSOLIDATED FINANCIAL STATEMENTS. SALUS HAS BEEN ORGANIZED AS A LIMITED LIABILITY COMPANY AND, ACCORDINGLY, IS NOT SUBJECT TO FEDERAL OR STATE INCOME TAXES. ALL INCOME TAX ATTRIBUTES OF THE ENTITY ARE PASSED THROUGH TO ITS SOLE MEMBER, WISCONSIN. THE ENTITY IS, HOWEVER, SUBJECT TO TEXAS FRANCHISE TAX. THE ENTITY IS INCLUDED IN THE CONSOLIDATED INFORMATION RETURN FILED BY VERSITI WISCONSIN. CENETRON HAS BEEN ORGANIZED AS A WHOLLY OWNED LLC THAT HAS ELECTED TO BE TREATED AS A C-CORPORATION FOR TAX PURPOSES AND SO IS SUBJECT TO FEDERAL AND STATE INCOME TAXES. INCOME TAXES ARE PROVIDED FOR THE TAX EFFECTS OF TRANSACTIONS REPORTED BY CENETRON AND CONSIST OF TAXES CURRENTLY DUE AND DEFERRED TAXES. DEFERRED TAXES ARE RECOGNIZED FOR DIFFERENCES BETWEEN THE BASIS OF ASSETS AND LIABILITIES FOR FINANCIAL STATEMENT AND INCOME TAX PURPOSES. THE DIFFERENCES RELATE PRIMARILY TO INTANGIBLE ASSETS. THE DEFERRED TAX ASSETS AND LIABILITIES REPRESENT THE FUTURE TAX RETURN CONSEQUENCES OF THOSE DIFFERENCES, WHICH WILL EITHER BE TAXABLE OR DEDUCTIBLE WHEN THE ASSETS AND LIABILITIES ARE RECOVERED OR SETTLED. CENETRON IS SUBJECT TO TAXATION IN THE UNITED STATES AND THE STATE OF TEXAS. QUANTIGEN HAS BEEN ORGANIZED AS A DISREGARDED ENTITY AND, ACCORDINGLY, IS NOT SUBJECT TO FEDERAL OR STATE INCOME TAXES. ALL INCOME TAX ATTRIBUTES OF THE ENTITY ARE PASSED THROUGH TO ITS SOLE MEMBER, WISCONSIN. PEARL PATHWAYS HAS BEEN ORGANIZED AS A DISREGARDED ENTITY AND, ACCORDINGLY, IS NOT SUBJECT TO FEDERAL OR STATE INCOME TAXES. ALL INCOME TAX ATTRIBUTES OF THE ENTITY ARE PASSED THROUGH TO ITS SOLE MEMBER, WISCONSIN. THE CONSOLIDATED DEFERRED TAX LIABILITY WAS $467,474 AND $675,285 AS OF DECEMBER 31, 2024 AND 2023, RESPECTIVELY, AND PRIMARILY RELATES TO INTANGIBLES. THERE WAS DEFERRED INCOME TAX EXPENSE FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023 OF $400,584 AND $371,200, RESPECTIVELY. THE ORGANIZATION RECOGNIZES, IF NECESSARY, INTEREST AND PENALTIES RELATED TO UNRECOGNIZED TAX BENEFITS IN THE PROVISION FOR INCOME TAXES. THERE WERE NO MATERIAL INTEREST OR PENALTIES RELATED TO INCOME TAXES THAT HAVE BEEN ACCRUED OR RECOGNIZED AS OF AND FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023. PART XI, LINE 4B - OTHER ADJUSTMENTS: CHANGES IN EQUITY IN CENETRON -504,088. GAIN ON DISPOSITION OF FIXED ASSETS 36,770. RENTAL ACTIVITY EXPENSES -12,144. INVESTMENT IN AFFILIATE BALANCE SHEET AMOUNT 1,430,000. FUNDRAISING EXPENSES -37,690. PART XII, LINE 2D - OTHER ADJUSTMENTS: BAD DEBT RESERVE ADJUSTMENT 374,084. GAIN ON DISPOSITION OF FIXED ASSETS -36,770. RENTAL ACTIVITY EXPENSES 12,144. FUNDRAISING EXPENSES 37,690. VERSITI ON KING LUNCH 91734 65534 26200 13975 23715 91734 65534 26200 13975 23715 37690 -11490 1 VERSITI BLOOD RESEARCH INSTITUTE FOUNDATION PO BOX 2178 638 N 18TH STREET MILWAUKEE WI 532012178 391372542 501(C)(3) 3810000 0 RESEARCH GREAT LAKES HEMOPHILIA FOUUNDATION INC 638 N 18TH ST MILWAUKEE WI 53233 237367636 501(C)(3) 129750 0 PATIENT FINANCIAL ASSISTANCE MARCUS PERFORMING ARTS CENTER 929 N WATER ST MILWAUKEE WI 53202 510532407 501(C)(3) 10000 0 GENERAL SUPPORT WISCONSIN STATE FAIR PARK FOUNDATION 640 S 84TH ST WEST ALLIS WI 53214 391840248 501(C)(3) 7000 0 GENERAL SUPPORT 4 SCHOLARSHIPS 1 4000 FMV PART I, LINE 2: PROCEDURE FOR MONITORING USE OF GRANT FUNDS INSIDE U.S. VERSITI WISCONSIN CONTINUES TO PROVIDE GRANT FUNDING TO VERSITI BLOOD RESEARCH INSTITUTE FOUNDATION, INC. AND OTHER TAX-EXEMPT ORGANIZATIONS. THESE FUNDS WILL SUPPORT FUTURE BLOOD RESEARCH AND OTHER INITIATIVES TO SERVE MORE PATIENTS AND REDUCE OVERALL COSTS. MONITORING THE INVESTMENT OF THESE FUNDS, THE DISTRIBUTIONS AND WHAT THESE FUNDS ARE USED FOR IS COMPLETED BY LEADERSHIP OF VERSITI WISCONSIN. ADDITIONALLY, THE FILING ORGANIZATION OFFERS SCHOLARSHIPS TO EMPLOYEES AND COMMUNITY MEMBERS IF CERTAIN CRITERIA ARE MET. THE SCHOLARSHIPS ARE SENT TO THE COLLEGE OR UNIVERSITY WHERE THE STUDENT IS ENROLLED. X X X X X 0 0 0 1 1 1 1 1 0 CHRIS MISKEL PRESIDENT & CEO 350722 446376 352309 448395 10909 13885 10626 13525 14748 18770 739314 940951 0 0 BART REUTER EVP & GENERAL COUNSEL 189439 241106 178380 227030 11283 14362 10626 13525 18433 23462 408161 519485 0 0 BRIAN BAUTISTA EVP & CHIEF OPERATING OFFICER 204932 260825 143060 182076 9623 12249 8081 10285 15499 19727 381195 485162 0 0 ANTHONY WATKINS EVP&CFO-THRU 3/24;BUS DEV-AS OF 3/24 144004 183278 155980 198520 29449 37480 10626 13525 2518 3207 342577 436010 0 0 MICHAEL DEININGER MD EVP & CHIEF SCIENTIFIC OFFICER 497386 26178 112195 5905 27499 1447 15090 794 22180 1167 674350 35491 0 0 BRADLEY PIETZ EVP & CHIEF LABORATORY OFFICER 135259 172151 117801 149929 11340 14435 10538 13413 18251 23228 293189 373156 0 0 JAMES WEIDNER EVP & CHIEF HR OFFICER 140199 178436 100156 127471 11149 14191 10626 13525 14361 18280 276491 351903 0 0 MATTHEW ANDERSON MD EVP & CHIEF MED. OFF. - AS OF 7/24 403926 0 65100 0 2842 0 24150 0 41700 0 537718 0 0 0 LYNNE BRIGGS VP & CHIEF INFORMATION OFFICER 141179 179684 67763 86243 3078 3919 11595 14758 11558 14711 235173 299315 0 0 DEREK TYUS EVP & CHIEF FINANCIAL OFF. - AS 3/24 144868 184379 52800 67200 1345 1712 10425 13268 10851 13809 220289 280368 0 0 KATHLEEN PUCA SR MEDICAL DIRECTOR 345435 0 67100 0 30022 0 27600 0 27900 0 498057 0 0 0 BARBARA BRYANT EVP & CHIEF MED. OFF. - THRU 8/24 328620 0 101700 0 17502 0 23946 0 1902 0 473670 0 0 0 CHRISTIAN J KASTRUP PHD SR INVESTIGATOR 377833 0 19900 0 1486 0 20250 0 41632 0 461101 0 0 0 KARIN HOFFMEISTER DEPUTY DIRECTOR VBRI 353991 0 41800 0 15255 0 14309 0 35019 0 460374 0 0 0 LISA BAUMANN KREUZIGER SENIOR MEDICAL DIRECTOR 345859 0 23800 0 25277 0 24150 0 16428 0 435514 0 0 0 GITESH DUBAL EVP & CHIEF MKTG. OFF. - THRU 4/24 56655 72103 113676 144678 8777 11171 4651 5920 5813 7397 189572 241269 0 0 LYNN M MALEC MD SENIOR MEDICAL DIRECTOR 361479 0 18100 0 4668 0 17926 0 16964 0 419137 0 0 0 JESSICA DROUILLARD VP & CHIEF QUALITY OFFICER 86807 110482 24376 31024 10272 13076 6776 8624 1543 1962 129774 165168 0 0 GRETCHEN JAMESON EVP & CHIEF MKTG. OFF. - AS OF 4/24 96463 122769 0 0 520 663 6042 7689 563 719 103588 131840 0 0 PART I, LINE 3 TOP MANAGEMENT'S COMPENSATION THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS, ACTING IN ITS CAPACITY AS THE COMPENSATION COMMITTEE, SETS AND MONITORS THE COMPENSATION PHILOSOPHY FOR THE FILING ORGANIZATION. OTHER THAN THE VERSITI PRESIDENT AND CHIEF EXECUTIVE OFFICER, THE EXECUTIVE COMMITTEE DOES NOT INCLUDE MEMBERS OF MANAGEMENT. TO ENSURE THAT THE COMMITTEE IS COMPRISED OF INDIVIDUALS WHO DO NOT HAVE A CONFLICT OF INTEREST WITH RESPECT TO VERSITI COMPENSATION ARRANGEMENTS, THE VERSITI PRESIDENT AND CHIEF EXECUTIVE OFFICER RECUSES HER/HIMSELF FROM ALL DISCUSSIONS AND APPROVALS RELATED TO HER/HIS COMPENSATION. THE EXECUTIVE COMMITTEE REVIEWS EXECUTIVE COMPENSATION ARRANGEMENTS TO ENSURE SUCH ARRANGEMENTS ARE FAIR, REASONABLE, AND NOT EXCESSIVE WHEN COMPARED TO SIMILARLY-SITUATED EXECUTIVES. EXECUTIVE COMPENSATION ARRANGEMENTS ARE REVIEWED FOR REASONABLENESS AND APPROVED BY THE EXECUTIVE COMMITTEE ANNUALLY IN ACCORDANCE WITH THE VERSITI REASONABLENESS REVIEW POLICY. IN ORDER TO ASSESS THE REASONABLENESS OF EXECUTIVE COMPENSATION ARRANGEMENTS, THE EXECUTIVE COMMITTEE OBTAINS AND REVIEWS APPROPRIATE COMPARABILITY DATA COLLECTED BY THE HUMAN RESOURCE DEPARTMENT AND/OR A QUALIFIED INDEPENDENT COMPENSATION CONSULTANT. THE EXECUTIVE COMMITTEE ENGAGES A QUALIFIED INDEPENDENT COMPENSATION CONSULTANT ANNUALLY. THE INDEPENDENT CONSULTANT PERFORMS AN ANALYSIS OF COMPENSATION LEVELS AT REGIONAL AND NATIONAL ORGANIZATIONS OF COMPARABLE SIZE, SCOPE AND STRUCTURE; AND PROVIDES THE COMMITTEE WITH COMPREHENSIVE DATA ON THE AVAILABILITY OF SIMILAR SERVICES WITHIN THE GEOGRAPHIC AREA, COMPENSATION SURVEYS, WRITTEN OFFERS FROM SIMILAR INSTITUTIONS, AND OTHER INFORMATION RELEVANT TO COMPARABILITY OF COMPENSATION. THE EXECUTIVE COMMITTEE'S REVIEW, RECOMMENDATIONS AND APPROVALS ARE DOCUMENTED CONCURRENTLY IN THE COMMITTEE MINUTES, WHICH ARE SUBSEQUENTLY REVIEWED AND APPROVED BY THE EXECUTIVE COMMITTEE AS REASONABLE, ACCURATE AND COMPLETE. THE COMMITTEE CHAIR VERBALLY COMMUNICATES TO THE BOARD OF DIRECTORS A CONFIRMATION OF COMPENSATION REASONABLENESS AND THE OVERALL DUE DILIGENCE PROCESS. VERSITI WISCONSIN HAS INCENTIVE PROGRAMS FOR EXECUTIVES, DIRECTORS, MANAGEMENT, INVESTIGATORS AND STAFF DESCRIBED IN DETAILED WRITTEN POLICIES APPROVED BY THE EXECUTIVE COMMITTEE ANNUALLY. EVALUATION AND COMPENSATION REVIEW -CEO - EACH YEAR, THE EXECUTIVE COMMITTEE EVALUATES THE CEO'S PERFORMANCE AGAINST ESTABLISHED OBJECTIVES, DETERMINES INCENTIVE PAYMENT AND MERIT INCREASE BASED UPON PERFORMANCE AND MARKET DATA PROVIDED BY THE THIRD PARTY COMPENSATION CONSULTANT, AND WORKS WITH THE CEO TO ESTABLISH OBJECTIVES FOR THE NEXT YEAR. -EXECUTIVES - THE BOARD OF DIRECTORS HAS DELAGATED TO THE CEO THE PERFORMANCE ASSESSMENT AND COMPENSATION DECISIONS FOR HIS/HER TEAM AND LEADERS ELIGIBLE FOR THE VERSITI LEADERSHIP INCENTIVE PLAN. DURING THE MAY MEETING, THE EXECUTIVE COMMITTEE REVIEWS THE INCENTIVES (SHORT AND LONG-TERM) PAYOUTS AND MERIT INCREASES ASSIGNED TO THE EXECUTIVE TEAM AS PART OF THE ANNUAL COMPENSATION REASONABILITY REVIEW CONDUCTED BY AON CONSULTANTS. THE EXECUTIVE COMMITTEE REVIEWS AND APPROVES THE SALARY INCREASES AND INCENTIVE PAYOUTS OF THE CEO BEFORE PAYMENT. EXECUTIVES ARE POSITIONED WITHIN THE APPROPRIATE SALARY RANGE BASED UPON THE: -EXECUTIVE'S KNOWLEDGE, COMPETENCIES, AND EXPERIENCE, -PERFORMANCE OF THE EXECUTIVE'S AREAS OF RESPONSIBILITY, -THE EXECUTIVE'S CONTRIBUTION TO OVERALL PERFORMANCE, -THE IMPORTANCE OF RETAINING THE EXECUTIVE, -INTERNAL EQUITY CONSIDERATIONS, -THE FINANCIAL RESOURCES AVAILABLE, AND -EXECUTIVE BASE SALARY INCREASES PROVIDED IN THE COMPETITIVE MARKET. PART I, LINE 5A, 5B, 6A, 6B AND 7: NON-FIXED PAYMENTS INCENTIVE PAYOUT OPPORTUNITIES, BASED ON PERCENTAGE OF BASE PAY RATE, ARE AVAILABLE TO CERTAIN EMPLOYEES OF THE FILING ORGANIZATION. WHILE LEVELS OF THE INCENTIVE PAYOUT OPPORTUNITY ARE FIXED AND DETERMINED PERCENTAGES OF BASE COMPENSATION, THE INCENTIVE PAYOUT IS DETERMINED, IN PART, ON THE CONSOLIDATED REVENUE AND NET EARNINGS OF OPERATING DIVISIONS. THE INCENTIVE PAYOUT IS SUBJECT TO THE REVIEW OF ACCOMPLISHMENTS/OBJECTIVES AND THE ULTIMATE DETERMINATION OF INCENTIVE COMPENSATION IS SUBJECT TO PRESIDENT/CEO AND EXECUTIVE COMMITTEE OF THE BOARD APPROVAL. FORM 990, PART I, LINE 1 VERSITI WISCONSIN, INC. (VERSITI WISCONSIN) IS A BLOOD HEALTH INNOVATOR WHICH ENHANCES LIVES THROUGH DISCOVERY, DIAGNOSIS AND TREATMENT. VERSITI EXPANDS THE FRONTIERS OF PATIENT HEALTH THROUGH THE INTEGRATION OF SCIENCE, MEDICINE AND SERVICE. FORM 990, PART VI, SECTION A, LINE 6 MEMBERS OR STOCKHOLDERS VERSITI, INC. IS THE SOLE CORPORATE MEMBER. FORM 990, PART VI, SECTION A, LINE 7A MEMBER OR STOCKHOLDER POWERS VERSITI, INC. HAS RESERVE POWERS; INCLUDING THE ABILITY TO ELECT A MAJORITY OF DIRECTORS. FORM 990, PART VI, SECTION A, LINE 7B REFER TO NARRATIVE LISTED IN LINE 7A. FORM 990, PART VI, SECTION B, LINE 11B FORM 990 REVIEW VERSITI WISCONSIN UTILIZES GRANT THORNTON TO COMPLETE THE IRS FORM 990 AND RELATED SCHEDULES. FOLLOWING COMPLETION, THEY ARE REVIEWED BY THE ORGANIZATION'S MANAGEMENT. THE DRAFT FORMS ARE THEN REVIEWED BY THE AUDIT AND COMPLIANCE COMMITTEE PRIOR TO SUBMISSION TO THE IRS. THE FULL BOARD IS PROVIDED A COPY OF THE FORM 990 PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C CONFLICT OF INTEREST POLICY VERSITI WISCONSIN MAINTAINS A WRITTEN CONFLICT OF INTEREST POLICY. ON AN ANNUAL BASIS, CURRENT DIRECTORS AND OFFICERS ARE ASKED TO COMPLETE A DISCLOSURE FORM BASED ON IRS REQUIREMENTS THAT INCLUDES THE FOLLOWING: WHETHER THEY HAVE ANY DIRECT OR INDIRECT RELATIONSHIP EITHER THROUGH BUSINESS OR FAMILY MEMBER WITH THE ORGANIZATION. WHETHER THEY RECEIVED COMPENSATION FROM ANY ORGANIZATION THAT SHARES COMMON OWNERSHIP OR CONTROL WITH THE ORGANIZATION. WHETHER THEY HAVE SERVED AS AN OFFICER, DIRECTOR, KEY EMPLOYEE, PARTNER OR MEMBER OF AN ENTITY (OR SHAREHOLDER OF A PROFESSIONAL CORPORATION) DOING BUSINESS WITH THE ORGANIZATION. THESE ANSWERS ARE ACCUMULATED, SUMMARIZED AND EVALUATED BY MANAGEMENT TO DETERMINE IF ANY CONFLICTS EXIST. IDENTIFIED CONFLICTS ARE ADDRESSED IN ACCORDANCE WITH THE WRITTEN POLICY. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION PROCESS THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS, ACTING IN ITS CAPACITY AS THE COMPENSATION COMMITTEE, SETS AND MONITORS THE COMPENSATION PHILOSOPHY FOR THE FILING ORGANIZATION. FORM 990, PART VI, SECTION C, LINE 19 ORGANIZATION'S DOCUMENTS OPEN TO THE PUBLIC THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE UPON REQUEST TO THE PUBLIC DURING NORMAL BUSINESS HOURS AND AT THE ORGANIZATION'S LOCATION. PART VII: AVERAGE HOURS THE HOURS LISTED ON FORM 990, PART VII ARE REPRESENTATIVE OF AN AVERAGE FOR THE OFFICERS AND EXECUTIVE TEAM. EACH INDIVIDUAL PERSON'S WEEKLY TALLY MAY BE GREATER OR LESSER PER WEEK BASED ON THEIR INDIVIDUAL ROLES AND RESPONSIBILITIES WITHIN THE FILING ORGANIZATION AND RELATED PARTIES. FORM 990, PART IX, LINE 11G SHIPPING & TRANSPORTATION: PROGRAM SERVICE EXPENSES 1,892,601. MANAGEMENT AND GENERAL EXPENSES 164,068. TOTAL EXPENSES 2,056,669. OUTSIDE LAB SERVICE: PROGRAM SERVICE EXPENSES 547,086. TOTAL EXPENSES 547,086. TEMPORARY HELP: PROGRAM SERVICE EXPENSES 445,420. MANAGEMENT AND GENERAL EXPENSES -40,335. TOTAL EXPENSES 405,085. SUBAWARDS: PROGRAM SERVICE EXPENSES 5,782,955. TOTAL EXPENSES 5,782,955. DONOR TESTING: PROGRAM SERVICE EXPENSES 5,744,886. TOTAL EXPENSES 5,744,886. PURCHASED SERVICES: PROGRAM SERVICE EXPENSES 1,255,534. MANAGEMENT AND GENERAL EXPENSES 495,400. TOTAL EXPENSES 1,750,934. ANIMAL CARE COSTS: PROGRAM SERVICE EXPENSES 1,331,489. TOTAL EXPENSES 1,331,489. CONSULTING SERVICES: PROGRAM SERVICE EXPENSES 1,353,566. MANAGEMENT AND GENERAL EXPENSES 56,399. TOTAL EXPENSES 1,409,965. OPERATING ROOM: PROGRAM SERVICE EXPENSES 1,163,168. TOTAL EXPENSES 1,163,168. IRB CONTRACTOR FEES: PROGRAM SERVICE EXPENSES 866,757. TOTAL EXPENSES 866,757. LAB: PROGRAM SERVICE EXPENSES 617,231. TOTAL EXPENSES 617,231. ICU: PROGRAM SERVICE EXPENSES 587,028. TOTAL EXPENSES 587,028. TRANSLATION SERVICE: PROGRAM SERVICE EXPENSES 491,172. TOTAL EXPENSES 491,172. PHARMACY: PROGRAM SERVICE EXPENSES 478,584. TOTAL EXPENSES 478,584. OTHER HOSPITAL CHARGES: PROGRAM SERVICE EXPENSES 386,278. TOTAL EXPENSES 386,278. GRADUATE STUDENT STIPENDS: PROGRAM SERVICE EXPENSES 363,637. TOTAL EXPENSES 363,637. RADIOLOGY: PROGRAM SERVICE EXPENSES 353,846. TOTAL EXPENSES 353,846. CLAIM/BILLING REVIEW: PROGRAM SERVICE EXPENSES 343,423. TOTAL EXPENSES 343,423. OUTSIDE MEDICAL DIRECTOR (OPO): PROGRAM SERVICE EXPENSES 338,895. TOTAL EXPENSES 338,895. CARDIOLOGY: PROGRAM SERVICE EXPENSES 309,386. TOTAL EXPENSES 309,386. FACILITY CHARGES: PROGRAM SERVICE EXPENSES 249,890. TOTAL EXPENSES 249,890. RESPIRATORY THERAPY: PROGRAM SERVICE EXPENSES 203,332. TOTAL EXPENSES 203,332. RECORD STORAGE: PROGRAM SERVICE EXPENSES 8,645. MANAGEMENT AND GENERAL EXPENSES 193,876. TOTAL EXPENSES 202,521. PHYSICIAN FEES: PROGRAM SERVICE EXPENSES 177,046. TOTAL EXPENSES 177,046. ANESTHESIA: PROGRAM SERVICE EXPENSES 159,955. TOTAL EXPENSES 159,955. LICENSES, PERMITS, & HOSP FEES: PROGRAM SERVICE EXPENSES 109,085. MANAGEMENT AND GENERAL EXPENSES 5,733. TOTAL EXPENSES 114,818. EDUCATION: PROGRAM SERVICE EXPENSES 73,611. MANAGEMENT AND GENERAL EXPENSES 33,663. TOTAL EXPENSES 107,274. DNA SEQUENCING: PROGRAM SERVICE EXPENSES 91,053. TOTAL EXPENSES 91,053. FUNERAL HOME CHARGES: PROGRAM SERVICE EXPENSES 85,305. TOTAL EXPENSES 85,305. PS SUPPLIES: PROGRAM SERVICE EXPENSES 84,572. TOTAL EXPENSES 84,572. CUSTOMER TESTING: PROGRAM SERVICE EXPENSES 54,813. TOTAL EXPENSES 54,813. PUBLICATION SERVICES: PROGRAM SERVICE EXPENSES 49,888. MANAGEMENT AND GENERAL EXPENSES 3,018. TOTAL EXPENSES 52,906. NON-MARKETING PRINTING COSTS : PROGRAM SERVICE EXPENSES 29,435. MANAGEMENT AND GENERAL EXPENSES 3,967. TOTAL EXPENSES 33,402. OUTSIDE CORE LAB CHARGES: PROGRAM SERVICE EXPENSES 25,836. TOTAL EXPENSES 25,836. OTHER PURCHASE SERV AFFILIATES: PROGRAM SERVICE EXPENSES 16,541. TOTAL EXPENSES 16,541. NON-HOSPITAL BUSINESS DEVELOPMENT: PROGRAM SERVICE EXPENSES 14,538. TOTAL EXPENSES 14,538. PHARMACY DISPENSING FEE: PROGRAM SERVICE EXPENSES 12,635. TOTAL EXPENSES 12,635. BANK ACCOUNT FEES: PROGRAM SERVICE EXPENSES 9,223. MANAGEMENT AND GENERAL EXPENSES 1,816. TOTAL EXPENSES 11,039. LAUNDRY COSTS: PROGRAM SERVICE EXPENSES 8,846. TOTAL EXPENSES 8,846. VARIABLE LEASES PRINTING SERVICES: MANAGEMENT AND GENERAL EXPENSES 588. TOTAL EXPENSES 588. MEDICAL REPORTS: PROGRAM SERVICE EXPENSES 79. TOTAL EXPENSES 79. EMPLOYMENT RECRUITMENT FEES: PROGRAM SERVICE EXPENSES 20. TOTAL EXPENSES 20. FORM 990, PART XI, LINE 9: BAD DEBT RESERVE ADJUSTMENT -374,084. CHANGE IN EQUITY IN CENETRON 504,088. INVESTMENT IN AFFILIATE BALANCE SHEET AMOUNT -1,430,000. RCRC INDEPENDENT REVIEW BOARD LLC 2111 W BRAKER LANE SUITE 100 AUSTIN TX 78758 390807235 REVIEW BOARD TX 5691154 4567553 VERSITI WI QUANTIGEN LLC 10300 KINCAID DR STE 200 FISHERS IN 46037 260229477 SPECIALTY LAB SERVICES IN 8575322 22717169 VERSITI WI PEARL IRB LLC 29 E MCCARTY ST STE 100 INDIANAPOLIS IN 46225 271927520 REGULATORY AFFAIRS CONSULTING SERVICES IN 3994527 11401801 VERSITI WI VERSITI BLOOD RESEARCH INSTITUTE FNDN PO BOX 2178 638 N 18TH ST MILWAUKEE WI 53201 391372542 SUPPORTING WI 501(C)(3) LINE 12B, II VERSITI 0 VERSITI INC PO BOX 2178 638 N 18TH ST MILWAUKEE WI 53201 454675354 SUPPORTING WI 501(C)(3) LINE 12B, II N/A 0 VERSITI ILLINOIS INC 1200 N HIGHLAND AVE AURORA IL 60506 362179768 BLOOD IL 501(C)(3) LINE 10 VERSITI 0 VERSITI MICHIGAN INC 1036 FULLER AVE NE GRAND RAPIDS MI 49503 381550001 BLOOD MI 501(C)(3) LINE 10 VERSITI 0 VERSITI INDIANA INC 3450 N MERIDIAN ST INDIANAPOLIS IN 46208 350991629 BLOOD IN 501(C)(3) LINE 10 VERSITI 0 CENETRON DIAGNOSTICS LLC 2111 W BRAKER LANE SUITE 300 AUSTIN TX 78758 742760677 LABS & TRIALS TX VERSITI WI C 504088 20800182 1.00000 1 0 1 1 0 0 1 1 1 0 0 1 1 1 1 1 1 1 0 0 CENETRON DIAGNOSTICS LLC F 1430000 FMV CENETRON DIAGNOSTICS LLC K 194293 FMV CENETRON DIAGNOSTICS LLC L 27260 FMV CENETRON DIAGNOSTICS LLC M 209428 FMV CENETRON DIAGNOSTICS LLC P 196806 FMV CENETRON DIAGNOSTICS LLC Q 351288 FMV